Sociedad Americana de Hirudoterapia

Effect of heavy metal lead on anticoagulant activity of leech based on label-free quantitative proteomics

Proteomics study published in China Journal of Chinese Materia Medica (2021)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaSeguridad y control de infeccionesXue M et al. · Zhongguo Zhong yao za zhi, 2021

Abstract

Whitmania pigra is the most widely distributed species of leeches in the market. In this study, the effect of heavy metal lead pollution on the anticoagulant activity of Wh. pigra was studied and the potential mechanism was explored. Pb(NO_3)_2 was used to contaminate the breeding soil which was then used to rear Wh. pigra for 50 days(lead-contaminated group, LC group), and meanwhile the blank control group(CG group) was set. Proteins were extracted from the obtained leech samples, and the differentially expressed proteins between LC and CG groups were analyzed by label-free proteomics technology. In this study, a total of 152 differentially expressed proteins were screened out, of which 93 proteins were up-regulated and 59 proteins were down-regulated in LC group. Bioinformatics analysis showed that the biological processes enriched with the differentially expressed proteins were mainly vesicle-mediated transport and transport positive regulation; the enriched cell components were mainly endocytosis vesicles and apical plasma membrane; the enriched molecular functions mainly included carbohydrate binding. The differentially expressed proteins were enriched in 76 KEGG pathways, which mainly involved metabolic pathways, biosynthesis of secondary metabolites, and bacterial invasion of epithelial cells. In this study, two differentially expressed proteins with Antistasin domain were presumed, which provides reference for further exploring the regulatory mechanism and signal transduction underlying the effect of lead pollution on the anticoagulant activity of leech.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsAnticoagulantsEnvironmental PollutionLeechesMetals, HeavyProteomics

Resumen

Label-free quantitative proteomics study showing lead contamination significantly alters leech anticoagulant proteome — identifies affected proteins.

Por qué esto importa para la hirudoterapia

This study used label-free quantitative proteomics to investigate the effect of heavy metal lead contamination on the anticoagulant activity of Whitmania pigra, comparing leeches reared in lead-contaminated soil for 50 days against a blank control group. A total of 152 differentially expressed proteins were identified (93 upregulated, 59 downregulated in the lead-contaminated group), with enrichment in metabolic pathways, biosynthesis of secondary metabolites, and bacterial invasion of epithelial cells; two differentially expressed proteins with Antistasin domains were identified as potentially relevant to changes in anticoagulant activity. This work is relevant to ASH's domain as it addresses a practical quality and safety concern—environmental heavy metal contamination—that could compromise the therapeutic potency of leech-derived materials. However, the study is proteomic and inferential, and the functional significance of the identified proteins for anticoagulant activity requires further targeted validation.

Citación

Effect of heavy metal lead on anticoagulant activity of leech based on label-free quantitative proteomics.

Xue M et al. · Zhongguo Zhong yao za zhi, 2021

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.